{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vinorelbine in Reference Text / Citation (approximate match)
Showing 1 - 10 of 10 results
Status:
US Approved Rx
(2012)
Source:
ANDA091106
(2012)
Source URL:
First approved in 1994
Source:
NAVELBINE by PIERRE FABRE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Vinorelbine (trade name Navelbine) is a semi-synthetic vinca-alkaloid with a broad spectrum
of anti-tumour activity. Vinorelbine is a mitotic spindle poison that impairs chromosomal segregation during mitosis. It blocks cells at G2/M. Microtubules (derived from polymers of tubulin) are the principal target of vinorelbine. Vinorelbine was developed by Pierre Fabre under licence from the CNRS in France. NAVELBINE (vinorelbine tartrate) as a single agent or in combination is indicated for the first line treatment of non small cell lung cancer and advanced breast cancer.
Status:
Investigational
Source:
INN:vinleurosine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Vinleurosine is a vinca alkaloid found in species of Catharanthus. This compound was studied as an anticancer agent and participated in clinical trials. However, the drug was more toxic and unpredictable in effect in comparison with vinblastine. Its further development was discontinued.
Status:
US Approved Rx
(2012)
Source:
ANDA091106
(2012)
Source URL:
First approved in 1994
Source:
NAVELBINE by PIERRE FABRE
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Vinorelbine (trade name Navelbine) is a semi-synthetic vinca-alkaloid with a broad spectrum
of anti-tumour activity. Vinorelbine is a mitotic spindle poison that impairs chromosomal segregation during mitosis. It blocks cells at G2/M. Microtubules (derived from polymers of tubulin) are the principal target of vinorelbine. Vinorelbine was developed by Pierre Fabre under licence from the CNRS in France. NAVELBINE (vinorelbine tartrate) as a single agent or in combination is indicated for the first line treatment of non small cell lung cancer and advanced breast cancer.
